APH-012
Obesity
Key Facts
About Aphaia Pharma
Aphaia Pharma is a Swiss clinical-stage biotech focused on revolutionizing the treatment of metabolic diseases through a novel oral drug delivery platform. Its lead candidate, APH-012, is a proprietary oral glucose formulation designed to activate nutrient-sensing cells in the distal small intestine, triggering a comprehensive hormonal response to control appetite and glucose metabolism. The company is currently advancing APH-012 in two Phase 2 trials for obesity and prediabetes, building on positive early clinical data. Led by an experienced team with deep industry and scientific expertise, Aphaia aims to provide long-term therapeutic benefits with minimal side effects by restoring the body's natural physiology.
View full company profileAbout Aphaia Pharma
Aphaia Pharma is a Swiss clinical-stage biotech focused on revolutionizing the treatment of metabolic diseases through a novel oral drug delivery platform. Its lead candidate, APH-012, is a proprietary oral glucose formulation designed to activate nutrient-sensing cells in the distal small intestine, triggering a comprehensive hormonal response to control appetite and glucose metabolism. The company is currently advancing APH-012 in two Phase 2 trials for obesity and prediabetes, building on positive early clinical data. Led by an experienced team with deep industry and scientific expertise, Aphaia aims to provide long-term therapeutic benefits with minimal side effects by restoring the body's natural physiology.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| RGT-075 | Regor Therapeutics | Phase 2b |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |